How to buy Pieris Pharmaceuticals stock (PIRS)

Pieris Pharmaceuticals is a biotechnology business based in the US. Pieris Pharmaceuticals shares (PIRS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $13.60 – the same closing value as a week prior. Pieris Pharmaceuticals employs 46 staff and has a trailing 12-month revenue of around $20.9 million.

Our top picks for where to buy Pieris Pharmaceuticals stock

Buy Pieris Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Pieris Pharmaceuticals stock price (NASDAQ: PIRS)

Use our graph to track the performance of PIRS stocks over time.

Pieris Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-22.

Latest market close	$13.60
52-week range	$6.20 - $22.32
50-day moving average more info button	$16.58
200-day moving average more info button	$13.79
Wall St. target price	$7.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-12.11

Is it a good time to buy Pieris Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pieris Pharmaceuticals price performance over time

Historical closes compared with the close of $13.6 from 2024-12-13

1 week (2024-12-17)	N/A
1 month (2024-11-27)	-19.19%
3 months (2024-09-27)	-15.84%
6 months (2024-06-28)	38.62%

1 year (2023-12-28)	7,184.41%
2 years (2022-12-28)	-82.11%
3 years (2021-12-28)	268.8
5 years (2019-12-27)	265.6

Pieris Pharmaceuticals financials

Revenue TTM	$20.9 million
Gross profit TTM	$-27,080,000
Return on assets TTM	-13.18%
Return on equity TTM	-80.46%
Profit margin	-114.12%
Book value	$21.64
Market Capitalization more info button	$21.1 million

TTM: trailing 12 months

Pieris Pharmaceuticals share dividends

We're not expecting Pieris Pharmaceuticals to pay a dividend over the next 12 months.

Have Pieris Pharmaceuticals's shares ever split?

Pieris Pharmaceuticals's shares were split on a 1:80 basis on 22 April 2024 . So if you had owned 80 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Pieris Pharmaceuticals shares – just the quantity. However, indirectly, the new 7900% higher share price could have impacted the market appetite for Pieris Pharmaceuticals shares which in turn could have impacted Pieris Pharmaceuticals's share price.

Pieris Pharmaceuticals share price volatility

Over the last 12 months, Pieris Pharmaceuticals's shares have ranged in value from as little as $6.2 up to $22.32. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pieris Pharmaceuticals's is 0.662. This would suggest that Pieris Pharmaceuticals's shares are less volatile than average (for this exchange).

Pieris Pharmaceuticals overview

Pieris Pharmaceuticals, Inc. , a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc. ; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts. .

Frequently asked questions

What percentage of Pieris Pharmaceuticals is owned by insiders or institutions?
Currently 0.066% of Pieris Pharmaceuticals shares are held by insiders and 52.921% by institutions. How many people work for Pieris Pharmaceuticals?
Latest data suggests 46 work at Pieris Pharmaceuticals. When does the fiscal year end for Pieris Pharmaceuticals?
Pieris Pharmaceuticals's fiscal year ends in December. Where is Pieris Pharmaceuticals based?
Pieris Pharmaceuticals's address is: 225 Franklin Street, Boston, MA, United States, 02110 What is Pieris Pharmaceuticals's ISIN number?
Pieris Pharmaceuticals's international securities identification number is: US7207951036 What is Pieris Pharmaceuticals's CUSIP number?
Pieris Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 720795103